Drug intelligence / Profile preview

simvastatin + cilostazol

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

A combination of simvastatin, an HMG-CoA reductase inhibitor used to treat hyperlipidemia, and cilostazol, a phosphodiesterase III inhibitor used for intermittent claudication and secondary stroke prevention. This combination is not marketed as a single product but represents a drug-drug interaction. Multiple doses of cilostazol increase the systemic exposure of simvastatin and its active metabolite, simvastatin acid, by 1.64-fold and 1.31-fold respectively, and increase their maximum concentrations by 1.8-fold and 1.6-fold.

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PDE3

Beyond the preview

Go deeper on simvastatin + cilostazol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on simvastatin + cilostazol.

Explore the full profile